

Topical Collection

MicroRNA in Health and Tumor

Message from the Collection Editor

MicroRNAs (miRNAs), short non-coding RNA, are involved in gene regulation, especially at the post-transcriptional level, and play a key role in a wide number of biological processes including differentiation, development, inflammation, immune response, drug resistance, and are usually dysregulated in many types of cancer. Moreover, miRNAs are differentially expressed in tumors compared to normal human tissues. Some of these altered miRNAs are overexpressed and known as oncomiR, which quicken tumor development, progression, dissemination. Contrarily, those that are downregulated in cancer patients are known as tumor suppressors. MiRNAs are also studied as biomarkers in clinical diagnosis and prognosis as well as indicator of treatment outcome and can be secreted as active molecule by different cell types. This Topical Collection aims to focus on the role of miRNAs in controlling pivotal biological mechanisms that lead to oncogenic transformation, including tumor formation, growth and dissemination, therapy resistance, as well as diagnostic and prognostic significance in different cancer subtypes.

Collection Editor

Collection Editor

Dr. Francesca Lovat

Comprehensive Cancer Center, Ohio State University, Columbus, OH
43210, USA



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/114105

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).